Medical encounters for TUD diagnosis in patients with T2DM and TUD (Comparision between matched semaglutide vs other anti-diabetes medications cohorts)

Size/cohort	Exposure	Comparison	cases (overall risk) (Exposure)	cases (overall risk) (Comparison)	RD (95% CI)		HR (95% CI)
5,954	semaglutide	insulins	1,168 (19.6%)	1,479 (24.8%)	-5.2% (-6.7%, -3.7%)	 ■ 	0.68 (0.63-0.74)
5,955	semaglutide	metformin	1,170 (19.6%)	1,372 (23.0%)	-3.4% (-4.9%, -1.9%)	H ≡ H	0.82 (0.76–0.88)
4,831	semaglutide	DPP-4i	923 (19.1%)	1,174 (24.3%)	-5.2% (-6.8%, -3.6%)	 ■ 	0.74 (0.67–0.80)
5,325	semaglutide	SGLT2i	1,046 (19.6%)	1,232 (23.1%)	-3.5% (-5.0%, -1.9%)	 ■ 	0.80 (0.74–0.87)
5,388	semaglutide	SU	1,042 (19.3%)	1,283 (23.8%)	-4.5% (-6.0%, -2.9%)	+■-1	0.76 (0.70–0.83)
2,659	semaglutide	TZD	462 (17.4%)	551 (20.7%)	-3.3% (-5.5%, -1.2%)	⊢■	0.78 (0.69–0.89)
5,337	semaglutide	other GLP-1RAs	1,051 (19.7%)	1,149 (21.5%)	-1.9% (-3.4%, -0.3%)	⊦ = ⊦	0.88 (0.81–0.96)
					C	0.30 0.40 0.60 0.801.0 Hazard Ratio (H	2.0 3.00 R)